KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ionis Pharmaceuticals (IONS) Cash & Current Investments (2016 - 2025)

Historic Cash & Current Investments for Ionis Pharmaceuticals (IONS) over the last 17 years, with Q3 2025 value amounting to $2.2 billion.

  • Ionis Pharmaceuticals' Cash & Current Investments fell 978.97% to $2.2 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $2.2 billion, marking a year-over-year decrease of 978.97%. This contributed to the annual value of $2.3 billion for FY2024, which is 143.9% down from last year.
  • Latest data reveals that Ionis Pharmaceuticals reported Cash & Current Investments of $2.2 billion as of Q3 2025, which was down 978.97% from $2.3 billion recorded in Q2 2025.
  • In the past 5 years, Ionis Pharmaceuticals' Cash & Current Investments registered a high of $2.5 billion during Q3 2024, and its lowest value of $1.8 billion during Q1 2021.
  • Moreover, its 5-year median value for Cash & Current Investments was $2.1 billion (2025), whereas its average is $2.2 billion.
  • Its Cash & Current Investments has fluctuated over the past 5 years, first tumbled by 2366.07% in 2021, then surged by 1798.18% in 2023.
  • Over the past 5 years, Ionis Pharmaceuticals' Cash & Current Investments (Quarter) stood at $2.1 billion in 2021, then decreased by 6.06% to $2.0 billion in 2022, then rose by 17.33% to $2.3 billion in 2023, then fell by 1.44% to $2.3 billion in 2024, then fell by 2.5% to $2.2 billion in 2025.
  • Its last three reported values are $2.2 billion in Q3 2025, $2.3 billion for Q2 2025, and $2.1 billion during Q1 2025.